Scholarlink

<p>Hematologic malignancies are a group of malignant diseases originating from hematopoietic stem cells or the lymphatic system, mainly including leukemia, lymphoma, myeloma and so on. These diseases are characterized by their high heterogeneity, rapid disease progression and poor prognosis. Glycosylation is one of the most common post-translational modifications. In recent years, it has been found that abnormal glycosylation plays an important role in the genesis, development and treatment of hematologic malignancies. Aberrant glycosylation has been demonstrated to exert a significant influence on the progression of disease, impacting various biological processes including tumor cell signaling, the tumor microenvironment, cellular recognition, and immune evasion. This review synthesizes recent advances in how dysregulated glycosylation drives the biology of leukemia, lymphoma, myeloma, and other types of malignancies. Additionally, it discusses the potential value of glycosylation products that can be used as biomarkers for disease diagnosis and prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Xiao Lu,
  • Zhouying Song,
  • Chunhui Wang,
  • Bing Pan,
  • Ziqi Xu,
  • Zilong Wang,
  • Hequn Wang,
  • Xiaobo Wang,
  • Bo Tang

摘要

Hematologic malignancies are a group of malignant diseases originating from hematopoietic stem cells or the lymphatic system, mainly including leukemia, lymphoma, myeloma and so on. These diseases are characterized by their high heterogeneity, rapid disease progression and poor prognosis. Glycosylation is one of the most common post-translational modifications. In recent years, it has been found that abnormal glycosylation plays an important role in the genesis, development and treatment of hematologic malignancies. Aberrant glycosylation has been demonstrated to exert a significant influence on the progression of disease, impacting various biological processes including tumor cell signaling, the tumor microenvironment, cellular recognition, and immune evasion. This review synthesizes recent advances in how dysregulated glycosylation drives the biology of leukemia, lymphoma, myeloma, and other types of malignancies. Additionally, it discusses the potential value of glycosylation products that can be used as biomarkers for disease diagnosis and prognosis.